Evidence map›Paper›PMID 39757352›Full record

Trial reportJournal of diabetes2025

TangBi Formula for Painful Diabetic Distal Symmetric Polyneuropathy: A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Parallel-Group Trial.

Xuefei Zhao, Xuedong An, Yashan Cui, Liu Dong, Zhaohui Fang, Zhonghua Zheng, Xinhe Zuo, Huailin Gao, Tianshu Gao, Qing Ni and 2 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xuefei ZhaoGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.ORCID https://orcid.org/0009-0006-1012-9686
Xuedong AnGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yashan CuiXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liu DongGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zhaohui FangThe First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, Anhui Province, China.
Zhonghua ZhengZhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, China.
Xinhe ZuoHubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei Province, China.
Huailin GaoHebei Yiling Hospital, Shijiazhuang, Hebei Province, China.
Tianshu GaoThe First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, China.
Qing NiGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Fengmei LianGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xiaolin TongGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

State Administration of Traditional Chinese Medicine of the People's Republic of China 201507001-11
6 · The paper itself

Abstract

objectiveTo determine whether the use of herbal medicines combined with conventional treatment is more effective than conventional medication alone in improving clinical symptoms in patients with diabetic distal symmetric polyneuropathy (DSPN).

methodsThis multicenter, placebo-controlled, double-blind, randomized controlled clinical trial recruited patients from 6 clinical centers in mainland China. A total of 188 patients were randomly assigned in a 1:1 ratio to the treatment group (Tangbi Formula plus methylcobalamin) and the control group (placebo plus methylcobalamin). Subjects were reassessed after the 24-week intervention. The primary outcomes were differences in changes in clinical signs and symptoms and changes in the Michigan Diabetic Neuropathy Score (MDNS) between the two groups before and after treatment. Secondary outcomes were changes in nerve conduction velocity (NCV) and single clinical signs and symptoms as measured by the visual-analogue scale (VAS) and Toronto clinical scoring system (TCSS).

resultsCompared with the placebo group, after 24 weeks of treatment, the MDNS score of TangBi Formula group was significantly reduced (p < 0.001). There were no significant changes in NCV results in either group before or after treatment. Compared with baseline, the difference in the change value of VAS score between the two groups after treatment was statistically significant (p = 0.031). A statistically significant difference in the change value of TCSS after treatment compared to baseline was found between the two groups (p = 0.033 at 12 weeks and p = 0.030 at 24 weeks). No severe adverse events due to study participation or study intervention were reported. CONCLUSIONS AND RELEVANCE: This trial demonstrated that combining Tangbi Formula with basal therapy can be safer and more effective in improving the symptoms of DSPN patients.

Indexed as

Diabetic NeuropathiesDrugs, Chinese HerbalVitamin B 12AdultAgedChinaDouble-Blind MethodFemaleHumansMaleMiddle AgedNeural ConductionTreatment OutcomeDrugs, Chinese HerbalmecobalaminVitamin B 12diabetesdiabetic distal symmetric polyneuropathyherbal therapyTCM

Identifiers

PMID39757352
PMCPMC11702395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.